Continuous circadian intracerebroventricular administration of anaerobically preserved dopamine greatly reduces severe L-dopa-related complications in Parkinson’s disease
Objective: We aim to demonstrate the safety and efficacy of continuous circadian intracerebroventricular (i.c.v.) administration of anaerobic-dopamine (A-dopamine) to reduce the L-dopa-related complications (LDRC) in…Efficacy of levodopa/benserazide dispersible tablet on delayed ON in Parkinson’s disease patients with motor fluctuations: a multicenter randomized open-label cross-over trial
Objective: This study aimed to assess the efficacy of levodopa/benserazide dispersible tablet on delayed ON in Parkinson’s disease (PD) patients with motor fluctuation. Background: Delayed…Multiple N-of-1 trials to investigate hypoxia therapy in Parkinson’s disease: TALISMAN study rationale and protocol
Objective: This is the first study that will assess the potential impact of hypoxia-based therapy in individuals with PD on respiratory parameters and PD symptoms.…Adverse drug reactions to apomorphine: a worldwide pharmacovigilancedatabase analysis
Objective: To determine the safety profile of apomorphine (expected vs. new signals), regardless of the indication and route of administration. Background: Adverse drug reactions (ADR)…Variability of Plasma Levodopa Conveniently Reduced by More Frequent Administration of Smaller Doses of Carbidopa/Levodopa Using a Novel Functionally Scored Formulation
Objective: To evaluate the pharmacokinetics (PK) of 25/100 mg carbidopa (CD)/levodopa (LD) compared to half that amount given twice as often using a new, deeply…Phantom Pregnancy – A Novel Impulse Control Behaviour in Parkinson’s Disease: A Case Report
Objective: A case report of a phantom pregnancy in a patient with Parkinson’s disease (PD) resulting from impulse control behaviour. Background: Impulse Control Disorders (ICDs)…Long-Term Safety and Efficacy of Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Europe vs North America
Objective: Evaluate long-term safety (LTS), tolerability, and efficacy of apomorphine sublingual film (APL) for on-demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD)…A Phase 2 Randomized Controlled Trial Repurposing Ambroxol as a Disease Modifying Treatment for Parkinson’s Disease Dementia.
Objective: Currently there are no disease-treatments for Synucleinopathies including Parkinson’s disease dementia (PDD). Our objective is to use Ambroxol to target GBA/Glucocerebrosidase to treat PDD.…Indirect Comparison of Apomorphine Sublingual Film Versus Levodopa Inhalation Powder for “OFF” Episodes in Parkinson’s Disease
Objective: Conduct a matching-adjusted indirect comparison (MAIC) of the efficacy of apomorphine sublingual film (APL) vs levodopa inhalation powder (CVT-301) for “OFF” episodes in Parkinson’s…SB-0107, a drug repurposing opportunity identified through machine learning, shows the potential to treat Parkinson’s disease motor disability and levodopa-induced dyskinesia in rat and primate models
Objective: To characterize the effects of a computationally identified small molecule in rat and primate models of Parkinson’s disease-associated motor deficits and treatment-associated complications. Background:…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 34
- Next Page »